Variable | |
Age (years) | 67 (median) (range 41–80) |
Referred patients | 452/564 (80%) |
Local patients | 112/564 (20%) |
Prostate weight (grams) | 64 (20–192) |
Initial PSA (μg/L) | 8.9 (median) (range 1.5–82.0) |
cT1c (%) | 327/564 (58%) |
cT2abc (%) | 215/564 (38%) |
cT3 (%) | 22/564 (4%) |
Biopsy Gleason 3+3=6/GG*-1 (%) | 276/564 (49%) |
Biopsy Gleason 3+4=7/GG-2 (%) | 143/564 (25%) |
Biopsy Gleason 4+3=7, 8, 9, 10/GG-3, 4, 5 (%) | 145/564 (26%) |
pT2 (%) | 400/564 (71%) |
pT3ab (%) | 164/564 (29%) |
Pathological Gleason 3+3=6/GG-1(%) | 216/564 (38%) |
Pathological Gleason 3+4=7/GG-2 (%) | 181/564 (32%) |
Pathological Gleason 4+3=7, 8, 9, 10/GG-3, 4, 5 (%) | 167/564 (30%) |
Total patients | 564 |
*GG, grade group (International Society of Urological Pathology); PSA, prostate specific antigen.